Skip to main content
Top
Published in: Tumor Biology 5/2016

01-05-2016 | Original Article

RETRACTED ARTICLE: Expression and prognostic value of the aldehyde dehydrogenase 1 (ALDH1) and N-myc downstream regulated gene 2 (NDRG2) as potential markers in human astrocytomas

Authors: Peyman Karimi Goudarzi, Farzad Mehrabi, Reza Jalili Khoshnood, Ali Baradaran Bagheri, Koorosh Ahmadi, Emad Yahaghi, Hesam Abdolhoseinpour

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

In this study, immunohistochemical analysis was used to evaluate the expression of ALDH1 and NDRG2 in astrocytoma tissue samples and normal brain tissues. ALDH1 protein staining displayed that AlDH1 expression was not detectable in eight astrocytoma tissues (8/36) and in all of normal brain tissues. There was a significant difference between ALDH1 expression and WHO grades (P = 0.03). Furthermore, no correlation was determined between expression levels of ALDH1 and other clinicopathological characteristics including age, sex, and tumor size. Immunohistochemistry showed that a high level of NDRG2 protein expression was markedly detected in normal brain tissues and expression of NDRG2 protein was significantly decreased in astrocytoma tissues. There was a significant association between pathological grading and NDRG2 expression level (P < 0.001, Table 1), but no correlation was determined between expression levels of NDRG2 and other clinicopathological characteristics including age, sex, and tumor size. We also obtained detailed follow-up data and evaluated the association of ALDH1/NDRG2 expressions with overall survival. Kaplan–Meier survival and log-rank analysis indicated that the patients with high proportion of ALDH1-positive cells and low proportion of NDRG2-positive had shorter overall survival (P < 0.001; P = 0.001). Univariate analysis indicated that the high proportion of ALDH1-positive cells (P < 0.001), the low proportion of NDRG2-positive cells (P = 0.009), and the advanced grade (P < 0.005) were markedly linked to the prognosis in patients. Furthermore, in the multivariate analysis, ALDH1 cells’ expression (P = 0.012), low proportion of NDRG2-positive cells (P = 0.025), and advanced grade (P < 0.03) were linked to poor overall survival. Our results suggest that NDRG2 expression is related to decreased survival rates and NDRG2 may be a potential marker in the astrocytoma prognosis. NDRG2 may be a potential marker in the astrocytoma prognosis. ALDH1 expression was related to advanced pathological grade and survival rate in astrocytoma patients.
Literature
1.
go back to reference Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedPubMedCentral Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedPubMedCentral
2.
go back to reference Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol. 2012;106:127–33.CrossRefPubMed Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol. 2012;106:127–33.CrossRefPubMed
3.
go back to reference Natsume A, Kato T, Kinjo S, Enomoto A, Toda H. Girdin maintains the stemness of glioblastoma stem cells. Oncogene. 2012;31:2715–24.CrossRefPubMed Natsume A, Kato T, Kinjo S, Enomoto A, Toda H. Girdin maintains the stemness of glioblastoma stem cells. Oncogene. 2012;31:2715–24.CrossRefPubMed
4.
go back to reference Wang Y, Li S, Chen L, You G, Bao Z. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14:518–25.CrossRefPubMedPubMedCentral Wang Y, Li S, Chen L, You G, Bao Z. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14:518–25.CrossRefPubMedPubMedCentral
5.
go back to reference Carico C, Nuno M, Mukherjee D, Elramsisy A, Dantis J. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One. 2012;7:e33684.CrossRefPubMedPubMedCentral Carico C, Nuno M, Mukherjee D, Elramsisy A, Dantis J. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One. 2012;7:e33684.CrossRefPubMedPubMedCentral
7.
go back to reference Stylli SS, Kaye AH, MacGregor L. Photodynamic therapy of high grade glioma—long term survival. J Clin Neurosci. 2005;12:389–98.CrossRefPubMed Stylli SS, Kaye AH, MacGregor L. Photodynamic therapy of high grade glioma—long term survival. J Clin Neurosci. 2005;12:389–98.CrossRefPubMed
8.
go back to reference Chu SH, Ma YB, Feng DF. Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci. 2012;19:95–8.CrossRefPubMed Chu SH, Ma YB, Feng DF. Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci. 2012;19:95–8.CrossRefPubMed
9.
go back to reference Chu SH, Feng DF, Ma YB. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med. 2011;9:156.CrossRefPubMedPubMedCentral Chu SH, Feng DF, Ma YB. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med. 2011;9:156.CrossRefPubMedPubMedCentral
10.
go back to reference Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000;129:1–19.CrossRefPubMed Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000;129:1–19.CrossRefPubMed
11.
go back to reference Patel M, Lu L, Zander DS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008;59:340–9.CrossRefPubMed Patel M, Lu L, Zander DS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008;59:340–9.CrossRefPubMed
13.
go back to reference Croker AK, Goodale D, Chu J. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13:2236–52.CrossRefPubMed Croker AK, Goodale D, Chu J. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13:2236–52.CrossRefPubMed
14.
go back to reference Su Y, Qiu Q, Zhang X. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:327–37.CrossRefPubMedPubMedCentral Su Y, Qiu Q, Zhang X. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:327–37.CrossRefPubMedPubMedCentral
15.
go back to reference Ginestier C, Hur MH, Charafe-Jauffret E, Monvile F, Dutcher J. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.CrossRefPubMedPubMedCentral Ginestier C, Hur MH, Charafe-Jauffret E, Monvile F, Dutcher J. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.CrossRefPubMedPubMedCentral
16.
go back to reference Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187–96.CrossRefPubMedPubMedCentral Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187–96.CrossRefPubMedPubMedCentral
17.
go back to reference Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1(5):485–7.CrossRefPubMed Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1(5):485–7.CrossRefPubMed
18.
go back to reference Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther. 2008;3(4):237–46.CrossRefPubMed Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther. 2008;3(4):237–46.CrossRefPubMed
19.
go back to reference Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X. NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol. 2004;10:3518–21.CrossRefPubMedPubMedCentral Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X. NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol. 2004;10:3518–21.CrossRefPubMedPubMedCentral
20.
go back to reference Hummerich L, Muller R, Hess J, Kokocinski F, Hahn M, Furstenberger G, et al. Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene. 2006;25:111–21.PubMed Hummerich L, Muller R, Hess J, Kokocinski F, Hahn M, Furstenberger G, et al. Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene. 2006;25:111–21.PubMed
21.
go back to reference Lorentzen A, Vogel LK, Lewinsky RH, Saebo M, Skjelbred CF, Godiksen S, et al. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer. 2007;7:192.CrossRefPubMedPubMedCentral Lorentzen A, Vogel LK, Lewinsky RH, Saebo M, Skjelbred CF, Godiksen S, et al. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer. 2007;7:192.CrossRefPubMedPubMedCentral
22.
go back to reference Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 2003;106:342–7.CrossRefPubMed Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 2003;106:342–7.CrossRefPubMed
23.
go back to reference Huang EH, Hynes MJ, Zhang T. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69:3382–9.CrossRefPubMedPubMedCentral Huang EH, Hynes MJ, Zhang T. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69:3382–9.CrossRefPubMedPubMedCentral
24.
go back to reference Awad O, Yustein JT, Shah P. High ALDH activity identifies chemotherapy resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 2010;5:e13943.CrossRefPubMedPubMedCentral Awad O, Yustein JT, Shah P. High ALDH activity identifies chemotherapy resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 2010;5:e13943.CrossRefPubMedPubMedCentral
25.
go back to reference Clay MR, Tabor M, Owen JH. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32:1195–201.CrossRefPubMedPubMedCentral Clay MR, Tabor M, Owen JH. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32:1195–201.CrossRefPubMedPubMedCentral
26.
go back to reference Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16(1):45–55.CrossRefPubMed Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16(1):45–55.CrossRefPubMed
27.
go back to reference Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385:307–13.CrossRefPubMed Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385:307–13.CrossRefPubMed
28.
go back to reference Liu DY, Ren CP, Yuan XR, Zhang LH, Liu J, Liu Q. ALDH1 expression is correlated with pathologic grade and poor clinical outcome in patients with astrocytoma. J Clin Neurosci. 2012;19(12):1700–5.CrossRefPubMed Liu DY, Ren CP, Yuan XR, Zhang LH, Liu J, Liu Q. ALDH1 expression is correlated with pathologic grade and poor clinical outcome in patients with astrocytoma. J Clin Neurosci. 2012;19(12):1700–5.CrossRefPubMed
29.
go back to reference Tanei T, Morimoto K, Shimazu K. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234–41.CrossRefPubMed Tanei T, Morimoto K, Shimazu K. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234–41.CrossRefPubMed
30.
go back to reference Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med. 2007;39:705–14.CrossRefPubMed Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med. 2007;39:705–14.CrossRefPubMed
31.
go back to reference Li L, Wang J, Shen X, Wang L, Li X, Liu Y. Expression and prognostic value of NDRG2 in human astrocytomas. J Neurol Sci. 2011;308(1–2):77–82.CrossRefPubMed Li L, Wang J, Shen X, Wang L, Li X, Liu Y. Expression and prognostic value of NDRG2 in human astrocytomas. J Neurol Sci. 2011;308(1–2):77–82.CrossRefPubMed
32.
go back to reference Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci. 2008;15:1198–203.CrossRefPubMed Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci. 2008;15:1198–203.CrossRefPubMed
33.
go back to reference Sun B, Chu D, Li W, Chu X, Li Y, Wei D. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol. 2009;94:213–9.CrossRefPubMed Sun B, Chu D, Li W, Chu X, Li Y, Wei D. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol. 2009;94:213–9.CrossRefPubMed
34.
go back to reference Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem. 2009;284:25160–9.CrossRefPubMedPubMedCentral Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem. 2009;284:25160–9.CrossRefPubMedPubMedCentral
35.
go back to reference Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008;123:2080–6.CrossRefPubMed Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008;123:2080–6.CrossRefPubMed
36.
go back to reference Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004–16.CrossRefPubMed Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004–16.CrossRefPubMed
37.
38.
go back to reference Shi H, Jin H, Chu D, Wang W, Zhang J, Chen C. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull. 2009;32:968–75.CrossRefPubMed Shi H, Jin H, Chu D, Wang W, Zhang J, Chen C. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull. 2009;32:968–75.CrossRefPubMed
39.
go back to reference Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C. Expression profile of the N-myc downstream regulated gene 2 (NDRG2) in human cancers with focus on breast cancer. BMC Cancer. 2011;11:14.CrossRefPubMedPubMedCentral Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C. Expression profile of the N-myc downstream regulated gene 2 (NDRG2) in human cancers with focus on breast cancer. BMC Cancer. 2011;11:14.CrossRefPubMedPubMedCentral
Metadata
Title
RETRACTED ARTICLE: Expression and prognostic value of the aldehyde dehydrogenase 1 (ALDH1) and N-myc downstream regulated gene 2 (NDRG2) as potential markers in human astrocytomas
Authors
Peyman Karimi Goudarzi
Farzad Mehrabi
Reza Jalili Khoshnood
Ali Baradaran Bagheri
Koorosh Ahmadi
Emad Yahaghi
Hesam Abdolhoseinpour
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4491-y

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine